Cancer Drug Pipeline Tracking Information - 2014

Updated: July 15, 2014
Pipeline Tracking Update - Objectives

- Review pipeline drugs that pCODR is tracking

Reasons for Tracking

- Inform provincial drug plans and cancer agencies to proactively manage implementation strategies
- Assist pCODR secretariat with resource management
Algorithm for Pipeline Tracking

1. Systemic Identification
   - Manufacturers survey
   - AHRQ Horizon Scanning
   - NIHR Horizon Scanning
   - FDA Hematology/Oncology (Cancer) Approvals
   - UK Medicines Information
   - pCODR Provincial Advisory Group

2. Filtration & Selection
   - Additional Information from NCIC CTG, ASCO, etc.
   - Assessment according to pCODR’s inclusion & exclusion criteria
   - pCODR’s anticipated submissions list
   - Health Canada NOC

3. Database Input
   - Drug Generic name
   - Indication
   - Tumour Group Panel
   - New Drug or New Indication
   - Companion Test
   - Route of Administration
   - Trial Status
   - Information Source
   - Reason, if no longer in pipeline

4. Annual Reporting of Aggregate Data to
   - pCODR Provincial Advisory Group
   - pCODR Advisory Committee
   - pCODR Expert Review Committee

©2014 CADTH-pCODR
Collection of Pipeline Information

**Inclusion Criteria**

- New chemical entity, vaccine, or biologic/targeted therapy that actively treat cancers
- New indications that do not have NOC
- Actively treat cancers
- Phase 2 or 3 clinical trial
- Multi-national trial locations or trial has at least one Canadian centre participating

**Exclusion Criteria**

- NOC received or NOC pending and pCODR submission expected
- Supportive treatment or symptom management
- Phase 1 trial
- Small local trial that do not have any Canadian or US centres participating
- Small local company overseas
Considerations for Estimating Submission Time & Numbers

- Potential submissions in next 12 months to more than 5 years
  - Some phase 2 trials are not expected to complete until 2019
- Not all will result in a submission to pCODR
  - Manufacturer decides not to seek licensing in Canada
  - Manufacturer decides not to submit for national funding review
  - Failed to meet trial outcomes or serious adverse events halts further development
  - Company mergers resulting in loss through attrition
- Several drug-indication pairs may be combined as one single submission to pCODR
- Manufacturers decide to submit after phase 2 trial or after interim analysis of phase 3 trial
Current Pipeline Drugs (as of March 31, 2014)

- Includes tumour group submissions, 2013-14 manufacturers survey results and pipeline drugs from other sources

- 25 manufacturers

- 120 distinct drugs
  - 82 new drugs
  - 38 existing drugs with new indications

- 242 drug-indication pairs
  - 147 new drugs-indications
  - 95 new indications for existing drugs
Current Pipeline Drugs by Route of Administration

Of the 82 Distinct New Drugs
(Not including existing drugs; Not drug- indication pairs)

- Intravenous: 39
- Oral: 36
- Other: 7

©2014 CADTH-pCODR
Current Pipeline Drugs by Trial Phase

Number of Drug-Indication Pairs

In Phase 2 Trials

- New Drug: 78%
- Existing Drug: 22%

In Phase 3 Trials

- New Drug: 45%
- Existing Drug: 55%
Current Pipeline Drugs by Tumour Group

- Breast
- Endocrine
- Gastrointestinal
- Genitourinary
- Gynecology
- Head and Neck
- Leukemia
- Lymphoma and Myeloma
- Lung
- Melanoma
- Neurological
- Other
- Sarcoma

Legend:
- Distinct Drugs
- Drug-Indication Pairs

©2014 CADTH-pCODR
Key Points

- Hematological cancers still has the most number of upcoming new drugs and new indications for existing drugs
- Many new molecular entities that have received NOC in the past year are undergoing clinical trials for expanded indications and for other tumours